FUSN Fusion Pharmaceuticals Inc. Stock Quote

FUSN [NASD]

Index	-	P/E	-	EPS (ttm)	-2.05	Insider Own	9.05%	Shs Outstand	41.78M	Perf Week	2.90%
Market Cap	356.48M	Forward P/E	-	EPS next Y	-1.93	Insider Trans	0.00%	Shs Float	33.07M	Perf Month	0.87%
Income	-85.60M	PEG	-	EPS next Q	-0.39	Inst Own	80.50%	Short Float	0.47%	Perf Quarter	-5.23%
Sales	-	P/S	-	EPS this Y	-831.10%	Inst Trans	-0.01%	Short Ratio	2.24	Perf Half Y	-27.88%
Book/sh	6.68	P/B	1.22	EPS next Y	-26.30%	ROA	-27.60%	Target Price	-	Perf Year	-39.76%
Cash/sh	5.20	P/C	1.57	EPS next 5Y	-	ROE	-28.70%	52W Range	6.61 - 14.31	Perf YTD	-30.64%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-43.05%	Beta	-
Dividend %	-	Quick Ratio	30.70	Sales past 5Y	-	Gross Margin	-	52W Low	23.35%	ATR	0.33
Employees	61	Current Ratio	30.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	50.01	Volatility	6.56% 3.39%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-50.60%	Profit Margin	-	Rel Volume	0.71	Prev Close	8.51
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 11 BMO	Payout	-	Avg Volume	70.22K	Price	8.15
Recom	1.60	SMA20	0.60%	SMA50	-0.51%	SMA200	-23.32%	Volume	49,946	Change	-4.23%

Jul-21-20

Initiated

Wedbush

Outperform

$25

Jul-21-20

Initiated

Jefferies

Buy

$25

Jul-21-20

Initiated

Cowen

Outperform

Jul-28-21 04:15PM	Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3 PR Newswire
04:15PM	Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3 CNW Group
Jul-07-21 08:00AM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08:00AM	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CNW Group
Jun-14-21 04:10PM	Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434 PR Newswire
04:10PM	Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434 CNW Group
Jun-07-21 04:10PM	Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. as Senior Vice President, Research PR Newswire
04:10PM	Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. as Senior Vice President, Research CNW Group
Jun-02-21 08:30AM	Fusion Pharmaceuticals Enters into Agreement to Build Radiopharmaceutical Manufacturing Facility PR Newswire
08:30AM	Fusion Pharmaceuticals Enters into Agreement to Build Radiopharmaceutical Manufacturing Facility CNW Group
May-27-21 04:05PM	Fusion Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference CNW Group
May-25-21 03:08AM	What Kind Of Shareholders Hold The Majority In Fusion Pharmaceuticals Inc.'s (NASDAQ:FUSN) Shares? Simply Wall St.
May-11-21 07:30AM	Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update PR Newswire
07:30AM	Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update CNW Group
May-06-21 10:46AM	Fusion Pharma Shares Move Higher After Trial Collab With Merck For IGF-1R-Expressing Cancer Study Benzinga
08:20AM	Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R PR Newswire
08:20AM	Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R CNW Group
Apr-14-21 08:45AM	Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference PR Newswire
08:45AM	Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference CNW Group
Apr-10-21 08:35AM	Fusion Pharmaceuticals Announces Preclinical Combination Data Demonstrating Enhanced Efficacy in Multiple Preclinical Tumor Models CNW Group
Apr-01-21 04:15PM	Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen PR Newswire
04:15PM	Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen CNW Group
08:00AM	Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors PR Newswire
08:00AM	Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors CNW Group
Mar-26-21 03:51AM	Are Insiders Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Stock? Simply Wall St. -5.95%
Mar-25-21 07:30AM	Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results and Business Update PR Newswire
07:30AM	Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results and Business Update CNW Group
Mar-02-21 07:30AM	Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen PR Newswire
07:30AM	Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen CNW Group
Feb-23-21 04:30PM	Fusion Pharmaceuticals To Present At The Cowen 41st Annual Health Care Conference PR Newswire
Feb-11-21 08:00AM	Fusion Pharmaceuticals Appoints Philina Lee, Ph.D., to Board of Directors PR Newswire
08:00AM	Fusion Pharmaceuticals Appoints Philina Lee, Ph.D., to Board of Directors CNW Group
Jan-25-21 12:40AM	Fusion Pharmaceuticals (NASDAQ:FUSN) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Jan-22-21 01:39PM	Cosmo Music and Music Tribe to Enter Super Partner Relationship CNW Group
Jan-11-21 07:30AM	/R E P E A T -- Media Advisory - CRTC to Hold a Virtual Hearing in Gatineau, Quebec/ CNW Group
Dec-16-20 09:00AM	TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope GlobeNewswire
Dec-10-20 06:24PM	Is FUSN A Good Stock To Buy Now? Insider Monkey
08:10AM	Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors PR Newswire
08:10AM	Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors CNW Group
Nov-26-20 12:36AM	What Is The Ownership Structure Like For Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)? Simply Wall St.
Nov-12-20 04:10PM	Fusion Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference PR Newswire
04:10PM	Fusion Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference CNW Group
Nov-10-20 07:00AM	Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update PR Newswire
07:00AM	Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update CNW Group
Nov-02-20 04:10PM	Fusion Pharmaceuticals Appoints Barbara Duncan as Chairperson of the Board of Directors PR Newswire
07:00AM	Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies PR Newswire
Oct-27-20 03:30PM	Orion Mine Finance Provides Update of its Ownership of Common Shares of Doré Copper Mining Corp. CNW Group
Sep-29-20 04:15PM	Fusion Pharmaceuticals Appoints Maria Stahl as Chief Legal Officer PR Newswire
Sep-27-20 10:18AM	Should You Take Comfort From Insider Transactions At Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)? Simply Wall St.
Sep-10-20 09:00AM	Fusion Pharmaceuticals to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference PR Newswire
Aug-11-20 07:25AM	Fusion Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update PR Newswire
Aug-05-20 08:00AM	Fusion Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference PR Newswire
Jul-14-20 09:30AM	H1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amount CNW Group
Jul-10-20 05:13PM	e.l.f. Beauty, Akouos See Activist Actions Barrons.com
Jun-25-20 10:39PM	Fusion Pharmaceuticals Announces Pricing of Initial Public Offering PR Newswire
10:39PM	Fusion Pharmaceuticals Announces Pricing of Initial Public Offering CNW Group

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ADAMS STREET PARTNERS LLC	10% Owner	Dec 24	Sale	12.32	3,800	46,816	418,190	Dec 29 04:01 PM
ADAMS STREET PARTNERS LLC	10% Owner	Dec 23	Sale	12.39	4,569	56,610	418,645	Dec 28 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience